NEJM:Tabrecta治疗METex14跳跃的非小细胞肺癌,关键研究取得积极结果

2020-09-03 Allan MedSci原创

MET是由MET基因编码的受体酪氨酸激酶,通常在细胞信号传导、增殖和存活中起重要作用。

近日,在《新英格兰医学杂志》(NEJM)上发表的关键性GEOMETRY mono-1 II期研究的数据显示,使用Tabrecta™(capmatinib)治疗MET外显子14(METex14)跳跃非小细胞肺癌的总缓解率(ORR)和反应持续时间(DOR)取得积极结果。

MET是由MET基因编码的受体酪氨酸激酶,通常在细胞信号传导、增殖和存活中起重要作用。许多癌症与MET受体途径的异常信号传导有关,这是由多种机制引起的,包括点突变、插入/缺失导致外显子14的跳跃。

诺华肿瘤学开发主管Jeff Legos说:“今天发表的数据不仅证实了我们之前在非小细胞肺癌中使用Tabrecta治疗所获得的积极结果,而且还强调了对患者肿瘤进行早期和广泛分子检测的价值,以指导治疗方案。我们知道患有这种侵袭性肺癌的患者预后较差,他们往往年龄较大。我们致力于与全球卫生当局合作,尽快将Tabrecta带给患者”。

独立放射学委员会(BIRC)对Tabrecta治疗MET外显子14跳跃患者(n = 97)进行了ORR分析,结果显示,初治患者(n = 28)的ORR率为68%(95%CI 48-84);先前接受过治疗的患者(n = 69)的ORR率为41%(95%CI 29-53)。

 

原始出处:

https://www.firstwordpharma.com/node/1754530?tsid=4

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896737, encodeId=ceac1896e37bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 24 23:37:58 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059926, encodeId=0245205992654, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Aug 04 19:37:58 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477163, encodeId=9cbe14e71632e, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat Sep 05 00:37:58 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850042, encodeId=73e01850042b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Jun 07 01:37:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035401, encodeId=1f7b10354015f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 03 12:37:58 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882423, encodeId=f2df882423c7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Sep 03 11:00:20 CST 2020, time=2020-09-03, status=1, ipAttribution=)]
    2021-05-24 一闲

    #MET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1896737, encodeId=ceac1896e37bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 24 23:37:58 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059926, encodeId=0245205992654, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Aug 04 19:37:58 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477163, encodeId=9cbe14e71632e, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat Sep 05 00:37:58 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850042, encodeId=73e01850042b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Jun 07 01:37:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035401, encodeId=1f7b10354015f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 03 12:37:58 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882423, encodeId=f2df882423c7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Sep 03 11:00:20 CST 2020, time=2020-09-03, status=1, ipAttribution=)]
    2021-08-04 lingaifan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896737, encodeId=ceac1896e37bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 24 23:37:58 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059926, encodeId=0245205992654, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Aug 04 19:37:58 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477163, encodeId=9cbe14e71632e, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat Sep 05 00:37:58 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850042, encodeId=73e01850042b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Jun 07 01:37:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035401, encodeId=1f7b10354015f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 03 12:37:58 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882423, encodeId=f2df882423c7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Sep 03 11:00:20 CST 2020, time=2020-09-03, status=1, ipAttribution=)]
    2020-09-05 Tamikia

    #Tabrecta#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1896737, encodeId=ceac1896e37bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 24 23:37:58 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059926, encodeId=0245205992654, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Aug 04 19:37:58 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477163, encodeId=9cbe14e71632e, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat Sep 05 00:37:58 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850042, encodeId=73e01850042b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Jun 07 01:37:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035401, encodeId=1f7b10354015f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 03 12:37:58 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882423, encodeId=f2df882423c7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Sep 03 11:00:20 CST 2020, time=2020-09-03, status=1, ipAttribution=)]
    2021-06-07 windight

    #CTA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1896737, encodeId=ceac1896e37bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 24 23:37:58 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059926, encodeId=0245205992654, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Aug 04 19:37:58 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477163, encodeId=9cbe14e71632e, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat Sep 05 00:37:58 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850042, encodeId=73e01850042b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Jun 07 01:37:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035401, encodeId=1f7b10354015f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 03 12:37:58 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882423, encodeId=f2df882423c7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Sep 03 11:00:20 CST 2020, time=2020-09-03, status=1, ipAttribution=)]
    2020-09-03 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1896737, encodeId=ceac1896e37bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=177, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon May 24 23:37:58 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059926, encodeId=0245205992654, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Aug 04 19:37:58 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477163, encodeId=9cbe14e71632e, content=<a href='/topic/show?id=41521e069a2' target=_blank style='color:#2F92EE;'>#Tabrecta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17069, encryptionId=41521e069a2, topicName=Tabrecta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5237352912, createdName=Tamikia, createdTime=Sat Sep 05 00:37:58 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850042, encodeId=73e01850042b2, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon Jun 07 01:37:58 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035401, encodeId=1f7b10354015f, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Sep 03 12:37:58 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882423, encodeId=f2df882423c7, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Sep 03 11:00:20 CST 2020, time=2020-09-03, status=1, ipAttribution=)]
    2020-09-03 139****0239

    很好

    0

相关资讯

PD-1单抗Opdivo联合贝伐单抗和化疗:显着改善非小细胞肺癌患者的无进展生存期

与安慰剂组相比,Opdivo组合组在无进展生存期(PFS)的主要终点方面显示出统计学上的显着改善,并且未发现新的安全问题。

Clini Cancer Res:SMARCA4突变可预测肺癌患者预后

SMARCA4突变是非小细胞肺癌(NSCLC)中最常见的复发性变异之一,但其与其他基因组异常的关系和临床影响尚未确定。本研究拟总结SMARCA4突变在NSCLC中的特征。

马学真教授:EGFR敏感突变晚期非小细胞肺癌NSCLC的全程管理要注重“线”的序贯和“面”的联合

随着医学研究的不断发展,肺癌早已进入精准医疗时代。EGFR敏感突变晚期非小细胞肺癌(NSCLC)的治疗策略又有怎样的更新呢?为大家深度剖析EGFR敏感突变晚期NSCLC治疗策略的优化。

Sci Rep:非小细胞肺癌患者使用术前营养控制状态评分(CONUT)预测术后肺部并发症

术前CONUT评分是手术切除NSCLC患者PPCs和1年死亡率的独立预测指标。

NEJM:肺癌治疗进展对死亡率的影响

2013-2016年,美国非小细胞肺癌患者的死亡率大幅下降,存活率大幅提高。随着治疗进展,发病率的降低,特别是靶向治疗的广泛使用是非小细胞肺癌患者死亡率下降的重要因素

NEJM:Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗

对于RET融合阳性非小细胞肺癌患者,Selpercatinib具有显著且持久的疗效

拓展阅读

对话大咖 | 张嘉涛教授:MRD提前预警复发之后,我们该立即干预还是密切监测?

【医悦汇】对话大咖栏目邀请到广东省人民医院张嘉涛教授,围绕MRD阳性后的干预时机、EGFR突变人群的停药管理、MRD标准化路径,以及早期清零后仍复发的病例特点与优化方向,展开深入探讨。

2026 WCLC|ORR超80%!PD‑L1/4‑1BB双抗联合化疗初显实力,黄岩教授解析下一代免疫双抗的机制、安全性与研发前景

2026世界肺癌大会(WCLC)上,中山大学肿瘤防治中心黄岩教授团队口头报告了这款双抗联合化疗一线治疗晚期非小细胞肺癌的Ⅱ期更新数据。

读书报告 |非小细胞肺癌进化特征

该研究为识别高播散潜力病灶、探索局部干预时机提供了生物学依据,但转移路径主要基于计算推断,染色体不稳定性的因果作用及干预获益仍需验证。

“以更高证据级别推动ctDNA临床应用落地,以剂型改造创新让老药焕发新生”,史美祺教授在肿瘤诊疗中的“创新解读”丨2026 CSCO年会

史美祺教授访谈提出ctDNA指导肺癌停药尚缺乏足够循证证据,临床需审慎;紫杉醇聚合物胶束剂型优势突出,联合信迪利单抗+铂类一线治疗非鳞NSCLC获78.6%ORR、18.2个月PFS。

研究发现:洋葱、柑橘中的这一物质,或能抗癌

槲皮素存在于洋葱、荞麦、柑橘,细胞与动物实验显示其多靶点调控、重塑肿瘤微环境、抑制非小细胞肺癌;尚无人体试验,饮食剂量不足,不能替代正规抗肿瘤治疗,具备联合辅助研究潜力。

死亡率排第一的癌,可以不用化疗了?

芦康沙妥珠单抗两项III期研究及ADVANCE随访为肺癌“去化疗”提供证据:PD-L1阴性一线ADC+免疫可替代含铂化疗;EGFR-TKI耐药后ADC单药OS优于化疗。